BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Meissner EG, Kohli A, Virtaneva K, Sturdevant D, Martens C, Porcella SF, McHutchison JG, Masur H, Kottilil S. Achieving sustained virologic response after interferon-free hepatitis C virus treatment correlates with hepatic interferon gene expression changes independent of cirrhosis. J Viral Hepat. 2016;23:496-505. [PMID: 26840694 DOI: 10.1111/jvh.12510] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Beinhardt S, Al-Zoairy R, Kozbial K, Stättermayer AF, Maieron A, Stauber R, Strasser M, Zoller H, Graziadei I, Rasoul-Rockenschaub S, Trauner M, Ferenci P, Hofer H. Long-term follow-up of ribavirin-free DAA-based treatment in HCV recurrence after orthotopic liver transplantation. Liver Int 2018;38:1188-97. [PMID: 29197145 DOI: 10.1111/liv.13652] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
2 Vakiti A, Cho MH, Lee W, Liang JJ, Lalos AT, Fishbein DA. Use of direct-acting antivirals for hepatitis C viral infection and association with intrahepatic cholangiocarcinoma: Is there a linkage? J Oncol Pharm Pract 2019;25:1743-8. [PMID: 30253731 DOI: 10.1177/1078155218800147] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Abdelaziz AO, Nabil MM, Abdelmaksoud AH, Shousha HI, Cordie AA, Hassan EM, Omran DA, Leithy R, Elbaz TM. De-novo versus recurrent hepatocellular carcinoma following direct-acting antiviral therapy for hepatitis C virus. Eur J Gastroenterol Hepatol. 2018;30:39-43. [PMID: 29064851 DOI: 10.1097/meg.0000000000001004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
4 Holmes JA, Yu ML, Chung RT. Hepatitis B reactivation during or after direct acting antiviral therapy - implication for susceptible individuals. Expert Opin Drug Saf. 2017;16:651-672. [PMID: 28471314 DOI: 10.1080/14740338.2017.1325869] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 6.6] [Reference Citation Analysis]
5 Tsetsarkin KA, Maximova OA, Liu G, Kenney H, Teterina N, Bloom ME, Grabowski JM, Mlera L, Nagata BM, Moore I, Martens C, Amaro-Carambot E, Lamirande EW, Whitehead SS, Pletnev AG. Routes of Zika virus dissemination in the testis and epididymis of immunodeficient mice. Nat Commun 2018;9:5350. [PMID: 30559387 DOI: 10.1038/s41467-018-07782-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
6 Meissner EG, Kohli A, Higgins J, Lee YJ, Prokunina O, Wu D, Orr C, Masur H, Kottilil S. Rapid changes in peripheral lymphocyte concentrations during interferon-free treatment of chronic hepatitis C virus infection. Hepatol Commun 2017;1:586-94. [PMID: 29202115 DOI: 10.1002/hep4.1074] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
7 Kozbial K, Moser S, Schwarzer R, Laferl H, Al-zoairy R, Stauber R, Stättermayer AF, Beinhardt S, Graziadei I, Freissmuth C, Maieron A, Gschwantler M, Strasser M, Peck-radosalvjevic M, Trauner M, Hofer H, Ferenci P. Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment. Journal of Hepatology 2016;65:856-8. [DOI: 10.1016/j.jhep.2016.06.009] [Cited by in Crossref: 139] [Cited by in F6Publishing: 146] [Article Influence: 23.2] [Reference Citation Analysis]
8 Wang XX, Luo BF, Jiang HJ, Cong X, Jin Q, Ma DL, Wei L, Feng B. Recovery of natural killer cells is mainly in post-treatment period in chronic hepatitis C patients treated with sofosbuvir plus ledipasvir. World J Gastroenterol 2018; 24(40): 4554-4564 [PMID: 30386105 DOI: 10.3748/wjg.v24.i40.4554] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
9 Zamor PJ, deLemos AS, Russo MW. Viral hepatitis and hepatocellular carcinoma: etiology and management. J Gastrointest Oncol 2017;8:229-42. [PMID: 28480063 DOI: 10.21037/jgo.2017.03.14] [Cited by in Crossref: 60] [Cited by in F6Publishing: 55] [Article Influence: 12.0] [Reference Citation Analysis]
10 Kushner T, Dieterich D, Saberi B. Direct-acting antiviral treatment for patients with hepatocellular carcinoma. Current Opinion in Gastroenterology 2018;34:132-9. [DOI: 10.1097/mog.0000000000000431] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
11 Orr C, Aartun J, Masur H, Kottilil S, Meissner EG. Characterization of changes in intrahepatic immune cell populations during HCV treatment with sofosbuvir and ribavirin. J Viral Hepat 2019;26:323-8. [PMID: 30383918 DOI: 10.1111/jvh.13034] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
12 Sato K, Kobayashi T, Yamazaki Y, Takakusagi S, Horiguchi N, Kakizaki S, Kusano M, Yamada M. Spontaneous remission of hepatitis B virus reactivation during direct-acting antiviral agent-based therapy for chronic hepatitis C: HBV reactivation during DAA-based therapy. Hepatol Res 2017;47:1346-53. [DOI: 10.1111/hepr.12905] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
13 Plissonnier ML, Herzog K, Levrero M, Zeisel MB. Non-Coding RNAs and Hepatitis C Virus-Induced Hepatocellular Carcinoma. Viruses. 2018;10. [PMID: 30380697 DOI: 10.3390/v10110591] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
14 Orr C, Xu W, Masur H, Kottilil S, Meissner EG. Peripheral blood correlates of virologic relapse after Sofosbuvir and Ribavirin treatment of Genotype-1 HCV infection. BMC Infect Dis 2020;20:929. [PMID: 33276734 DOI: 10.1186/s12879-020-05657-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Moradpour D, Grakoui A, Manns MP. Future landscape of hepatitis C research - Basic, translational and clinical perspectives. J Hepatol. 2016;65:S143-S155. [PMID: 27641984 DOI: 10.1016/j.jhep.2016.07.026] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
16 Meissner EG, McLaughlin M, Matthews L, Gharib AM, Wood BJ, Levy E, Sinkus R, Virtaneva K, Sturdevant D, Martens C, Porcella SF, Goodman ZD, Kanwar B, Myers RP, Subramanian M, Hadigan C, Masur H, Kleiner DE, Heller T, Kottilil S, Kovacs JA, Morse CG. Simtuzumab treatment of advanced liver fibrosis in HIV and HCV-infected adults: results of a 6-month open-label safety trial. Liver Int. 2016;36:1783-1792. [PMID: 27232579 DOI: 10.1111/liv.13177] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 8.7] [Reference Citation Analysis]
17 Casadei Gardini A, Foschi FG, Conti F, Petracci E, Vukotic R, Marisi G, Buonfiglioli F, Vitale G, Ravaioli F, Gitto S, Verucchi G, Lenzi M, Bolondi L, Mazzella G, Brillanti S, Andreone P. Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals. Digestive and Liver Disease 2019;51:681-8. [DOI: 10.1016/j.dld.2018.09.016] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 8.7] [Reference Citation Analysis]
18 Ogawa E, Furusyo N, Nomura H, Dohmen K, Higashi N, Takahashi K, Kawano A, Azuma K, Satoh T, Nakamuta M, Koyanagi T, Kato M, Shimoda S, Kajiwara E, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group. Short-term risk of hepatocellular carcinoma after hepatitis C virus eradication following direct-acting anti-viral treatment. Aliment Pharmacol Ther. 2018;47:104-113. [PMID: 29035002 DOI: 10.1111/apt.14380] [Cited by in Crossref: 55] [Cited by in F6Publishing: 52] [Article Influence: 11.0] [Reference Citation Analysis]
19 Lim EJ, Torresi J. Prevention of Hepatitis C Virus Infection and Liver Cancer. Recent Results Cancer Res 2021;217:107-40. [PMID: 33200364 DOI: 10.1007/978-3-030-57362-1_6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Miyasaka A, Yoshida Y, Suzuki A, Masuda T, Okamoto H, Takikawa Y. Hepatitis B virus reactivation after successful treatment of hepatitis C virus with sofosbuvir and ribavirin: A case report and literature review. Medicine (Baltimore) 2020;99:e22650. [PMID: 33031326 DOI: 10.1097/MD.0000000000022650] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
21 Villani R, Facciorusso A, Bellanti F, Tamborra R, Piscazzi A, Landriscina M, Vendemiale G, Serviddio G. DAAs Rapidly Reduce Inflammation but Increase Serum VEGF Level: A Rationale for Tumor Risk during Anti-HCV Treatment. PLoS One 2016;11:e0167934. [PMID: 27997563 DOI: 10.1371/journal.pone.0167934] [Cited by in Crossref: 56] [Cited by in F6Publishing: 60] [Article Influence: 9.3] [Reference Citation Analysis]
22 Pradat P, Virlogeux V, Trépo E. Epidemiology and Elimination of HCV-Related Liver Disease. Viruses 2018;10:E545. [PMID: 30301201 DOI: 10.3390/v10100545] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 7.3] [Reference Citation Analysis]
23 Elbaz T, Waked I, El-Akel W, Shaker MK, Abdelaziz AO, Yousif M, El-Bendary M, Zaky S, AbdAllah M, Hassany M, Esmat G, Doss W. Impact of successful HCV treatment using direct acting antivirals on recurrence of well ablated hepatocellular carcinoma. Expert Rev Anti Infect Ther 2021;:1-8. [PMID: 34253123 DOI: 10.1080/14787210.2021.1951230] [Reference Citation Analysis]
24 Sato K, Yamazaki Y, Kobayashi T, Takakusagi S, Horiguchi N, Kakizaki S, Andou M, Matsuda Y, Uraoka T, Ohnishi H, Okamoto H. Sofosbuvir/Ribavirin therapy for patients experiencing failure of ombitasvir/paritaprevir/ritonavir + ribavirin therapy: Two cases report and review of literature. World J Clin Cases 2019; 7(9): 1043-1052 [PMID: 31123677 DOI: 10.12998/wjcc.v7.i9.1043] [Reference Citation Analysis]
25 Carmona I, Cordero P, Ampuero J, Rojas A, Romero-Gómez M. Role of assessing liver fibrosis in management of chronic hepatitis C virus infection. Clin Microbiol Infect 2016;22:839-45. [PMID: 27677698 DOI: 10.1016/j.cmi.2016.09.017] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
26 Nault JC, Colombo M. Hepatocellular carcinoma and direct acting antiviral treatments: Controversy after the revolution. J Hepatol. 2016;65:663-665. [PMID: 27417216 DOI: 10.1016/j.jhep.2016.07.004] [Cited by in Crossref: 75] [Cited by in F6Publishing: 81] [Article Influence: 12.5] [Reference Citation Analysis]
27 Cucchetti A, D'Amico G, Trevisani F, Morelli MC, Vitale A, Pinna AD, Cescon M; from the Special Interest Group on Hepatocellular carcinoma and new anti HCV therapies of the Italian Association for the Study of the Liver (AISF). Effect of direct-acting antivirals on future occurrence of hepatocellular carcinoma in compensated cirrhotic patients. Dig Liver Dis 2018;50:156-62. [PMID: 29102521 DOI: 10.1016/j.dld.2017.10.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
28 Balagopal A, Smeaton LM, Quinn J, Venuto CS, Morse GD, Vu V, Alston-Smith B, Cohen DE, Santana-Bagur JL, Anthony DD, Sulkowski MS, Wyles DL, Talal AH. Intrahepatic Viral Kinetics During Direct-Acting Antivirals for Hepatitis C in Human Immunodeficiency Virus Coinfection: The AIDS Clinical Trials Group A5335S Substudy. J Infect Dis 2020;222:601-10. [PMID: 32201883 DOI: 10.1093/infdis/jiaa126] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
29 Obajemu AA, Rao N, Dilley KA, Vargas JM, Sheikh F, Donnelly RP, Shabman RS, Meissner EG, Prokunina-Olsson L, Onabajo OO. IFN-λ4 Attenuates Antiviral Responses by Enhancing Negative Regulation of IFN Signaling. J Immunol 2017;199:3808-20. [PMID: 29070670 DOI: 10.4049/jimmunol.1700807] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 8.2] [Reference Citation Analysis]